L-type Ca++ CP γ5 Inhibitors
The chemical compounds that act as L-type Ca++ CP γ5 (LTCC) inhibitors include a variety of structural classes. Dihydropyridines, such as nifedipine and amlodipine, bind to specific sites on the LTCC and preferentially block the influx of calcium ions into cells. This blockade is particularly effective in vascular smooth muscle cells, leading to vasodilation and reduced contraction. Phenylalkylamines, exemplified by verapamil, and benzothiazepines, such as diltiazem, display a different binding profile and kinetics, but they ultimately lead to a similar outcome in terms of reducing calcium entry into cells.
Beyond the vascular effects, the decrease in calcium influx can influence the activity of proteins involved in neurotransmitter release, muscle contraction, and other signaling pathways. For example, proteins that are part of synaptic vesicle fusion machinery or those that regulate gene expression in response to calcium signaling may exhibit reduced activity in the presence of LTCC inhibitors. Each LTCC inhibitor has a distinct affinity for the L-type calcium channel, and some, like mibefradil, can also affect T-type calcium channels. The specificity and potency of these inhibitors can vary, leading to differential effects on cellular calcium dynamics. The compounds like flunarizine also possess additional properties, such as the blockade of other ion channels, and may influence cellular processes beyond those regulated by LTCCs.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil can block L-type calcium channels, reducing calcium influx into cells, potentially decreasing the activity of calcium-dependent proteins. | ||||||
Diltiazem | 42399-41-7 | sc-204726 sc-204726A | 1 g 5 g | $209.00 $464.00 | 4 | |
Diltiazem can inhibit L-type calcium channels, altering intracellular calcium levels and potentially modulating the function of calcium-sensitive proteins. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine can selectively inhibit L-type calcium channels, altering the signaling pathways that depend on calcium, such as those possibly involving the protein. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
Amlodipine, an L-type calcium channel blocker, can reduce calcium entry into cells, potentially affecting proteins reliant on calcium signaling. | ||||||
Isradipine | 75695-93-1 | sc-201467 sc-201467A | 10 mg 50 mg | $88.00 $324.00 | 1 | |
Isradipine selectively targets L-type calcium channels, potentially diminishing the activity of calcium-dependent proteins. | ||||||
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $61.00 $307.00 | 2 | |
Nimodipine can preferentially inhibit L-type calcium channels in cerebral arteries, potentially influencing calcium-mediated cellular processes. | ||||||
Bepridil | 64706-54-3 | sc-507400 | 100 mg | $1620.00 | ||
Bepridil can inhibit both L-type calcium channels and other ion channels, potentially affecting cellular activities that involve calcium signaling. | ||||||
Mibefradil dihydrochloride | 116666-63-8 | sc-204083 sc-204083A | 10 mg 50 mg | $213.00 $865.00 | 4 | |
Mibefradil can inhibit T-type and L-type calcium channels, which may alter the function of proteins that are regulated by calcium influx. | ||||||
trans Lacidipine | 103890-78-4 | sc-213066 | 10 mg | $153.00 | ||
Lacidipine can block L-type calcium channels, potentially affecting downstream signaling and the activity of proteins that require calcium for their function. | ||||||
Flunarizine | 52468-60-7 | sc-337841 | 5 g | $560.00 | ||
Flunarizine can inhibit calcium entry through L-type calcium channels, potentially modifying the activity of proteins involved in calcium signaling. | ||||||